PGx preventive panel

Synonyms: -

Material:

EDTA blood
(1 ml), buccal swab

TAT:

2 weeks

Method:

AmpliconSEQ, NGS

Overview

Preventive pharmacogenetic panel provides information on inherited genetic variants that may be relevant to future medication use. This screening test analyses 25 pharmacogenes associated with drug metabolism, response and drug-safety risk factors across multiple therapeutic areas. Results are reported as genotype and phenotype together with pharmacogenetic annotations, where available. The test is intended for informational purposes and is not a medical diagnostic test.

Pharmacological background

Tested variants

Result interpretation

Test limitations

Clinical relevance

References

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical pharmacology and therapeutics. 2018;103(2):210-216. doi: 10.1002/cpt.911. PMID: . PMCID: PMC5760397.
Maillard M, Schwab M, Whirl-Carrillo M, Moyer AM, Suarez-Kurtz G, Pui CH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update. Clinical pharmacology and therapeutics. 2026;119(4):916-927. doi: 10.1002/cpt.70209. PMID: . PMCID: PMC12997511. Correction: PMID .
Hulshof EC, Deenen MJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, et al. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan. European journal of human genetics : EJHG. 2023;31(9):982-987. doi: 10.1038/s41431-022-01243-2. PMID: . PMCID: PMC10474017. Correction: PMID .
Bergmann TK, Brasch-Andersen C, Gréen H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. The pharmacogenomics journal. 2011;11(2):113-20. doi: 10.1038/tpj.2010.19. PMID: .
US Food and Drug Administration. Warfarin sodium tablets, prescribing information (ANDA040301); Clinical Pharmacology 12.5 Pharmacogenomics, CYP2C9 and VKORC1. Label current 29 July 2021.
European Medicines Agency. Plavix (clopidogrel) EPAR, product information; CYP2C19 pharmacogenomics section. Product information current 14 July 2025.
Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clinical pharmacology and therapeutics. 2022;111(5):1007-1021. doi: 10.1002/cpt.2557. PMID: . PMCID: PMC9035072.
US Food and Drug Administration. Codeine sulfate tablets, prescribing information (NDA022402); CYP2D6 Genetic Variability, ultra-rapid metabolizers. Label current 22 December 2025.
US Food and Drug Administration. Prograf (tacrolimus) prescribing information (NDA050708); Clinical Pharmacology, metabolism by CYP3A4 and CYP3A5. Label current 25 August 2023.
US Food and Drug Administration. Efavirenz tablets, prescribing information (ANDA091579); Drug Interaction Studies, CYP2B6-mediated metabolism. Label current 28 June 2024.
European Medicines Agency. Fasturtec (rasburicase) EPAR, product information, section 4.3: G6PD deficiency as a contraindication. Product information current 12 August 2024.
Gammal RS, Pirmohamed M, Somogyi AA, Morris SA, Formea CM, Elchynski AL, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clinical pharmacology and therapeutics. 2023;113(5):973-985. doi: 10.1002/cpt.2735. PMID: . PMCID: PMC10281211.
European Medicines Agency. Xeloda (capecitabine) EPAR, product information; DPYD section. Product information current 2 May 2025.
European Medicines Agency. Xaluprine (mercaptopurine) EPAR, product information; TPMT and NUDT15 sections. Product information current 25 September 2025.
Lunenburg CATC, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. European journal of human genetics : EJHG. 2020;28(4):508-517. doi: 10.1038/s41431-019-0540-0. PMID: . PMCID: PMC7080718.
Coenen MJH, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between TPMT/NUDT15 and thiopurines. European journal of human genetics : EJHG. 2026;34(1):152-160. doi: 10.1038/s41431-025-01986-8. PMID: . PMCID: PMC12816135.

Created by

Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.

Last content review: August 4, 2026. As pharmacogenomic evidence and recommendations continue to evolve, the information presented on this page may not always reflect the latest updates. For current guidance and annotations, please refer to .

Last Update : 06.10.2026

How to order a genetic test

Select the right test for your patients. Contact our team in case you do not have an active contract yet.

Collect the sample. Download and fill in the order and consent form or access our portal (available for sample sent to Germany).

Properly pack the sample and send it to Medicover Genetics.

The sample will be analysed in our accredited laboratories.

An actionable report will be available for you to access safely and securely.

Get in touch with us

Our team of experts is here to support you at every stage.

Your role *

Please select the option that best describes you.

FIRST NAME *

Please enter your first name.

LAST NAME *

Please enter your last name.

PHONE

Providing your phone number is optional and helps us contact you more quickly if needed.

EMAIL ADDRESS *

Please enter a valid email address

Country *

Please provide your country of residence. This information is required to route your request to the appropriate sales representative based on your location.

ORGANISATION / INSTITUTION

Please enter your organisation / institution

MESSAGE / ADDITIONAL NOTES

Please do not enter sensitive health data or special categories of personal data here. If you need to share such information, please use a secure, separate communication channel, such as encrypted email, a protected patient portal or a confidential phone call.

Your data will be used solely for processing your inquiry. For more information on how we handle your personal data and your rights, please refer to our .